The Damaging Outcome of the POLAR Phase III Trials Was Due to Avoidable Time-Dependent Redox Interaction between Oxaliplatin and PledOx

On 2 July 2021, highly negative results were reported from the POLAR A and M phase III trials in patients with colorectal cancer, treated with an oxaliplatin-based regimen and co-treated with calmangafodipir (CaM; PledOx(®); PledPharma AB/Egetis Therapeutics AB) or placebo. The results revealed pers...

Descripción completa

Detalles Bibliográficos
Autores principales: Karlsson, Jan Olof G., Jynge, Per, Ignarro, Louis J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750726/
https://www.ncbi.nlm.nih.gov/pubmed/34943040
http://dx.doi.org/10.3390/antiox10121937

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750726/
https://www.ncbi.nlm.nih.gov/pubmed/34943040
http://dx.doi.org/10.3390/antiox10121937

Ejemplares similares